source
- Argenx to acquire macrocycle biotech Unnatural Products in up to $1.15 billion dealArgenx announced Monday it will acquire Unnatural Products, a biotech focused on macrocycle therapeutics that began as a garage startup. The transaction is structured as an up-to-$1.15 billion dea…
- Zura Bio halts hidradenitis suppurativa program after tibulizumab fails phase 2 trialZura Bio announced it is ending development of tibulizumab for hidradenitis suppurativa after the drug did not meet the primary endpoint in a phase 2 study. The trial, called Tibushield, compared t…